ASCO Gastrointestinal Cancers Symposium 2027: What's Coming to GI Oncology's Flagship Research Meeting

Every January, the American Society of Clinical Oncology (ASCO) convenes the field's leading gastrointestinal (GI) cancer specialists for a few concentrated days of new data — and GI oncology has quietly become one of immunotherapy's most active growth areas. The 2027 ASCO Gastrointestinal Cancers Symposium is scheduled for January 21–23, 2027, at Moscone West in San Francisco, with a virtual attendance option for those who can't travel. Here's what the meeting is, why it matters for anyone following cancer immunotherapy, and what readers can realistically expect from it.

When and Where

The symposium runs January 21–23, 2027, at Moscone West (800 Howard Street, San Francisco), ASCO's recurring West Coast venue for this meeting. It is organized by ASCO, often with co-sponsorship from allied gastroenterology and oncology societies in past years. The event combines in-person scientific sessions, poster presentations, and abstract talks with a digital option, making it accessible to clinicians and researchers who can't attend in person.

Why GI Cancers Are a Growing Immunotherapy Frontier

Gastrointestinal cancers — colorectal, gastric, esophageal, pancreatic, hepatobiliary — have historically been harder for immunotherapy to crack than melanoma or lung cancer, in part because many GI tumors have a less "immunogenic" profile. That's been changing. Checkpoint inhibitors are now standard of care in subsets of GI cancer defined by biomarkers such as microsatellite instability, and 2026 brought genuine, well-documented momentum: the FDA approved the first adjuvant immunotherapy regimen for a common form of stage III colon cancer based on the NCI-funded ATOMIC trial, and bispecific antibody combinations have shown real activity in advanced biliary tract cancer in randomized Phase 3 testing. Pancreatic cancer remains the field's stubborn exception — immunotherapy still performs poorly there, largely due to a particularly suppressive tumor microenvironment — which makes it a frequent topic of discussion at meetings like this one as researchers search for ways around that barrier.

What to Expect on the Agenda

ASCO GI typically features plenary sessions on practice-changing trial data, disease-specific tracks (colorectal, pancreatic, hepatobiliary, gastroesophageal, anal/rectal), and a heavy emphasis on combination strategies — pairing checkpoint inhibitors, bispecific antibodies, or antibody-drug conjugates with chemotherapy or targeted agents. Attendees should expect updates on biomarker-driven patient selection (which patients actually benefit from immunotherapy in GI cancers remains an active research question), real-world data on recently approved regimens, and early-phase trial results for cell and gene therapy approaches that remain experimental in solid GI tumors. As with any conference preview, the specific headline results for January 2027 aren't public yet — abstracts are typically released shortly before the meeting — so this is a preview of the meeting's scope and focus rather than its findings.

Who Attends and How to Follow Along

The symposium draws medical oncologists, surgical oncologists, radiation oncologists, GI fellows, and industry scientists, alongside patient advocates and journalists covering oncology. For a reader simply trying to track where GI cancer immunotherapy is headed, the practical takeaway is less about any single late-breaking abstract and more about the trend line: a field that was largely immunotherapy-resistant a decade ago is now accumulating real, randomized evidence of benefit in specific GI cancer subtypes, even as others (pancreatic cancer chief among them) remain largely unmoved.

Bottom Line

ASCO GI 2027 is a legitimate, well-established academic and industry meeting — not a marketing event — and its growing immunotherapy content reflects a real shift in a cancer category that was long considered resistant to these approaches. Readers interested in GI cancer treatment should treat conference previews as a guide to what's being studied, not a substitute for peer-reviewed, published trial results once they're available.